BACKGROUND: Literature data examining the role of metabolic syndrome and its components in prostate cancer risk are limited and contradictory. AIM: We did a meta-analysis of studies that evaluated the association between metabolic syndrome, its components, and risk of prostate cancer. SUBJECTS AND METHODS: We conducted an electronic search for articles published through September 2012 without restrictions. Every included study was to report risk estimates with 95% confidence intervals for the association between metabolic syndrome and prostate cancer. RESULTS: The final number of papers included in the meta-analysis was 14, all published in English, with 4728 prostate cancer cases. Metabolic syndrome was associated with a 12% increase in prostate cancer risk (p=0.231), that was lower in cohort studies (7 studies, RR=1.04, p=0.791) than other studies (RR=1.23, p=0.125). The association was significant in the 8 European studies (RR=1.30, p=0.034), but not in the 4 U.S. or 2 Asiatic studies. The risk estimates of prostate cancer for higher values of body mass index, dysglycemia or dyslipidemia (high triglycerides, low HDL-cholesterol) were not significant; on the contrary, hypertension and waist circumference >102 cm were associated with a significant 15% (p=0.035) and 56% (p=0.007) greater risk of prostate cancer, respectively. CONCLUSIONS: Metabolic syndrome is weakly and non significantly associated with prostate cancer risk, but associations vary with geography. Among single components of the syndrome, hypertension and higher waist circumference are significantly associated with increased risk of prostate cancer.
BACKGROUND: Literature data examining the role of metabolic syndrome and its components in prostate cancer risk are limited and contradictory. AIM: We did a meta-analysis of studies that evaluated the association between metabolic syndrome, its components, and risk of prostate cancer. SUBJECTS AND METHODS: We conducted an electronic search for articles published through September 2012 without restrictions. Every included study was to report risk estimates with 95% confidence intervals for the association between metabolic syndrome and prostate cancer. RESULTS: The final number of papers included in the meta-analysis was 14, all published in English, with 4728 prostate cancer cases. Metabolic syndrome was associated with a 12% increase in prostate cancer risk (p=0.231), that was lower in cohort studies (7 studies, RR=1.04, p=0.791) than other studies (RR=1.23, p=0.125). The association was significant in the 8 European studies (RR=1.30, p=0.034), but not in the 4 U.S. or 2 Asiatic studies. The risk estimates of prostate cancer for higher values of body mass index, dysglycemia or dyslipidemia (high triglycerides, low HDL-cholesterol) were not significant; on the contrary, hypertension and waist circumference >102 cm were associated with a significant 15% (p=0.035) and 56% (p=0.007) greater risk of prostate cancer, respectively. CONCLUSIONS:Metabolic syndrome is weakly and non significantly associated with prostate cancer risk, but associations vary with geography. Among single components of the syndrome, hypertension and higher waist circumference are significantly associated with increased risk of prostate cancer.
Authors: Jennifer L Beebe-Dimmer; Rodney L Dunn; Aruna V Sarma; James E Montie; Kathleen A Cooney Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Maria D Jackson; Susan P Walker; Candace M Simpson; Norma McFarlane-Anderson; Franklyn I Bennett; Kathleen C M Coard; William D Aiken; Trevor Tulloch; Tomlin J Paul; Robert L Wan Journal: Cancer Causes Control Date: 2010-02-16 Impact factor: 2.506
Authors: Richard M Martin; Lars Vatten; David Gunnell; Pål Romundstad; Tom I L Nilsen Journal: Cancer Causes Control Date: 2009-03-11 Impact factor: 2.506
Authors: Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben Journal: Cochrane Database Syst Rev Date: 2020-06-04
Authors: C De Nunzio; G Truscelli; A Trucchi; S Petta; M Tubaro; M Gacci; C Gaudio; F Presicce; A Tubaro Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Elisabeth Möller; Kathryn M Wilson; Julie L Batista; Lorelei A Mucci; Katarina Bälter; Edward Giovannucci Journal: Int J Cancer Date: 2015-09-23 Impact factor: 7.396
Authors: Axel Gerdtsson; Jessica B Poon; Daniel L Thorek; Lorelei A Mucci; Michael J Evans; Peter Scardino; Per-Anders Abrahamsson; Peter Nilsson; Jonas Manjer; Anders Bjartell; Johan Malm; Andrew Vickers; Stephen J Freedland; Hans Lilja; David Ulmert Journal: Eur Urol Date: 2015-03-18 Impact factor: 20.096
Authors: Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal Journal: BJU Int Date: 2014-10-20 Impact factor: 5.588